Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.
While chimeric antigen receptor (CAR) T-cell therapy has offered a new option and improved outcomes for patients with advanced hematologic malignancies, the treatment approach has been associated with toxicities such as cytokine release syndrome (CRS), neurotoxicity, and hematotoxicity.
A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
Nancy Reau, MD, section chief of hepatology at Rush University Medical Center, elaborates on survey results showing providers have varying awareness and understanding on guidelines for chronic liver disease.
A panel including several experts in cardiology discussed the ways that heart failure (HF) can be diagnosed and treated using the new 2022 AHA/ACC/HFSA Guidelines.
Patient-Centered Oncology Care® (PCOC) begins Wednesday in Tennessee with 2 days of discussions on how to achieve the related goals of closing health care disparities and eliminating barriers for patients.
Kashyap Patel, MD, president of Community Oncology Alliance and chief executive officer of Carolina Blood and Cancer Care Associates, previews the Patient-Centered Oncology Care® (PCOC) 2022 meeting happening this week in Nashville, Tennessee.
The Department of Veterans Affairs (VA) will give cancer claims priority when a new law takes effect in January 2023; Pfizer is looking to use its COVID-19 profits to grow other blockbusters; the probable loss of Medicaid coverage for millions next year is setting off debate.
Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.
Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, professor of medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the results of the recently halted FRESH trial, why there is such a great need for new antihypertensive agents, and possible contributory factors to outcome disparities between Black and White patients.
Posters presented at the American Heart Association's Scientific Sessions elaborated on the results of out-of-pocket expenses and adherence for guideline-directed medical therapies in patients with heart failure with reduced ejection fraction (HFrEF).
The DELIVER trial is the largest trial to date of SGLT2 inhibitor use in heart failure, and these latest data on dapagliflozin in heart failure with mildly reduced or preserved ejection fraction show an extensive benefit on health status, noted Mikhail Kosiborod, MD, cardiologist at St. Luke's Mid America Heart Institute in Kansas City, Missouri.
The Supreme Court will hear a nursing home case Tuesday that could have far-reaching consequences; COVID-19 is continuing to take a toll on worker productivity; ultra-processed foods are linked to premature deaths in a new study.
A panel at the annual American Heart Association conference held in Chicago, Illinois, discussed ways in which cardiovascular disease (CVD) care was affected by equity issues between White and Black patients.
Tom Robinson, vice president of global access at JDRF, talks about the data collection process in creating the Type 1 Diabetes (T1D) Index.
To try to get a prescription digital therapeutic (PDT) covered, manufacturers need to align the value of their product to the priority of the payer, said Kelly Price, US head of rare disease at HRA Pharma.
Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, talks about what oncology agents in the pipeline he hopes to see become available.
The latest real-world clinical practice data from the VICTORIA trial of vericiguat bolster previous data on the medication’s benefit by showing that 92% of patients hospitalized for a worsening heart failure event would be eligible to start the therapy and that doing so would reduce their risk of heart failure hospitalization and cardiovascular death, noted Stephen J. Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.
Posters presented at the American Heart Association conference in Chicago, Illinois, evaluated the insights from the VICTORIA trial and their generalizability to patients hospitalized with heart failure with reduced ejection fraction (HFrEF).
The analysis emphasizes the association between vaso-occlusive crisis frequency and health care costs, which are inflated largely due to inpatient visits.
Gene therapy is a novel approach to hemophilia A treatment that carries a substantial cost up front but may lead to cost savings compared with current prophylaxis agents in the long run.
Recent research suggested the idea of combining chimeric antigen receptor (CAR) T-cell therapy and Bruton’s tyrosine kinase (BTK) inhibitors for certain patients with advanced mantle cell lymphoma (MCL).
A new report underscores how treatment decisions for non-small cell lung cancer (NSCLC) affect patients’ health care utilization and costs.
In the ENNOBLE-ATE trial, Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's, and his team evaluated the safety and efficacy of edoxaban, a direct oral anticoagulant previously only used among adult patients, among pediatric patients with cardiac disease.
Daniel E. Weiner, MD, MS, board certified nephrologist and lead navigator at Tufts Clinical and Translational Science Institute, spoke on the limitations and future potential of value-based payment systems for chronic kidney disease (CKD), including the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Models.
A decline in eye care utilization was found in older patients, with significant differences based on age, race, and ethnicity.
Curtis Warfield, MS, senior quality analyst, Indiana State Department of Health, and regional leader of National Kidney Foundation's Kidney Advocacy Committee, spoke on limitations regarding the current process of educating and managing lifestyle interventions for patients with chronic kidney disease (CKD), and how nephrologists can better integrate these strategies.
More than 1 in 4 adults have 1 or more conditions that fall into the cardio-renal-metabolic category, according to findings released during Kidney Week 2022.
Douglas L. Mann, MD, professor of medicine at Washington University School of Medicine in St. Louis and editor-in-chief of JACC: Basic to Translational Science discussed the first set of data reported on NTLA-2001, a novel investigative intravenous agent that targets the TTR gene and TTR protein levels, which have been shown to play a role in development of cardiac transthyretin (ATTR) amyloidosis.
